Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart

• Published in: Journal of thrombosis and haemostasis 2017-08, Vol.15 (8), p.1620-1624
• Main Authors: Reich, H. J., Morgan, J., Arabia, F., Czer, L., Moriguchi, J., Ramzy, D., Esmailian, F., Lam, L., Dunhill, J., Volod, O.
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - blood; Bleeding; Comparative analysis; Down-Regulation; etiology; Female; Health risk assessment; Heart; heart failure; Heart Failure - blood; Heart Failure - diagnosis; Heart Failure - physiopathology; Heart Failure - therapy; Heart, Artificial - adverse effects; Heart-Assist Devices - adverse effects; heart‐assist devices; hemorrhage; Hemorrhage - blood; Hemorrhage - diagnosis; Hemorrhage - etiology; Humans; Male; Middle Aged; Morbidity; Prosthesis Design; Protein Multimerization; Retrospective Studies; Risk Factors; Ristocetin; Time Factors; Treatment Outcome; Ventricle; Ventricular Function, Left; von Willebrand diseases; Von Willebrand factor; von Willebrand Factor - metabolism
• ISSN: 1538-7933; 1538-7836; 1538-7836
• DOI: 10.1111/jth.13753

Essentials Bleeding is a major source of morbidity during mechanical circulatory support. von Willebrand factor (VWF) multimer loss may contribute to bleeding. Different patterns of VWF multimer loss were seen with the two device types. This is the first report of total artificial heart associated VWF multimer loss. Summary Background Bleeding remains a challenge during mechanical circulatory support and underlying mechanisms are incompletely understood. Functional von Willebrand factor (VWF) impairment because of loss of high‐molecular‐weight multimers (MWMs) produces acquired von Willebrand disease (VWD) after left ventricular assist device (LVAD). Little is known about VWF multimers with total artificial hearts (TAHs). Here, VWF profiles with LVADs and TAHs are compared using a VWD panel. Methods VWD evaluations for patients with LVAD or TAH (2013‐14) were retrospectively analyzed and included: VWF activity (ristocetin cofactor, VWF:RCo), VWF antigen (VWF:Ag), ratio of VWF:RCo to VWF:Ag, and quantitative VWF multimeric analysis. Results Twelve patients with LVADs and 12 with TAHs underwent VWD evaluation. All had either normal (47.8%) or elevated (52.2%) VWF:RCo, normal (26.1%) or elevated (73.9%) VWF:Ag and 50.0% were disproportional (ratio ≤ 0.7). Multimeric analysis showed abnormal patterns in all patients with LVADs: seven with high MWM loss; five with highest MWM loss. With TAH, 10/12 patients had abnormal patterns: all with highest MWM loss. High MWM loss correlated with presence of LVAD and highest MWM loss with TAH. Increased low MWMs were detected in 22/24. Conclusion Using VWF multimeric analysis, abnormalities after LVAD or TAH were detected that would be missed with measurements of VWF level alone: loss of high MWM predominantly in LVAD, loss of highest MWM in TAH, and elevated levels of low MWM in both. This is the first study to describe TAH‐associated highest MWM loss, which may contribute to bleeding.